Staphylococcus Aureus Infections - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 01/27/2014 -- Reportstack, provider of premium market research reports announces the addition of Staphylococcus Aureus Infections - Pipeline Review, H2 2013 market report to its offering
Staphylococcus Aureus Infections - Pipeline Review, H2 2013


, 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Staphylococcus Aureus Infections - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections.
- A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Staphylococcus Aureus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Staphylococcus Aureus Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

AstraZeneca PLC
GlaxoSmithKline plc
Genentech, Inc.
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Exploit Technologies Pte Ltd
Novartis AG
Actelion Ltd
Pfizer Inc.
Wockhardt Limited
NovaBay Pharmaceuticals, Inc.
Patrys Limited
Galapagos NV
Microbio Co., Ltd.
Morphotek, Inc.
Bharat Biotech International Limited
Novabiotics Ltd
GlycoVaxyn AG
Priaxon AG
Aquapharm Biodiscovery Limited
Aridis Pharmaceuticals LLC
NovaDigm Therapeutics, Inc.
Microbiotix, Inc.
Integrated BioTherapeutics, Inc.
Ancora Pharmaceuticals Inc.
Phico Therapeutics Ltd.
GangaGen Inc.
Omnia Molecular Ltd.
MGB Biopharma Limited
Absynth Biologics Limited
Furiex Pharmaceuticals, Inc.
Sanofi Pasteur SA
Lascco SA
Agilvax, Inc.
Biota Pharmaceuticals, Inc.
Biomar Microbial Technologies
Humabs BioMed SA
ImmunNovative Developments SL
Abgentis Limited
Melinta Therapeutics Inc.
Telephus Medical LLC
Infexion Ltd.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604